MA
CRSP icon

MYDA Advisors’s CRISPR Therapeutics CRSP Stock Holding History

MYDA Advisors’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-5,000
Closed -$327K – 91
2022
Q3 		$327K Sell
5,000
-5,000
-50% -$362K 0.15% 105
2022
Q2 		$608K Buy
+10,000
New +$588K 0.17% 111

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GP
GSK plc London $599M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

MYDA Advisors's CRSP Position: Q1 2020 in Review

MYDA Advisors sold out of CRISPR Therapeutics (CRSP) in Q1 2020, closing a stake of 14,000 shares — an estimated $853K sold.

MYDA Advisors first reported a position in CRSP in Q4 2019 and held it in 1 quarter. The position peaked at $853K in Q4 2019. 257 funds tracked by Wall St. Rank hold CRSP as of Q1 2020.

  • MYDA Advisors reported no remaining CRISPR Therapeutics position as of Q1 2020 after selling out during the quarter.
  • MYDA Advisors sold 14,000 CRISPR Therapeutics shares in Q1 2020, an estimated $853K.
  • MYDA Advisors first reported a position in CRISPR Therapeutics in Q4 2019 and held it in 1 quarter.
  • MYDA Advisors's CRISPR Therapeutics position peaked at $853K in Q4 2019.
  • 257 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2020.

Based on MYDA Advisors's 13F filing for Q1 2020, filed 14 May 2020.